Elevated Plasma S100B, Psychotic Symptoms, and Cognition in Schizophrenia
S100B is a calcium binding protein mainly produced by glial cells. Previous studies have shown elevated levels of S100B in patients with schizophrenia. We measured S100B levels in fasting plasma of 39 patients with schizophrenia and 19 adult healthy controls. We used linear regression to compare S100B between patients and controls. In patients only, we also investigated the relationship between S100B levels and psychotic symptoms (assessed by the Positive and Negative Syndrome Scale), and cognitive function (assessed by the NIH Toolbox Cognition Battery), respectively by calculating Pearson’s correlation coefficients. Mean plasma S100B was significantly higher in the patient group than in the control group. There were no significant correlations between plasma S100B and psychotic symptoms or cognition.
KeywordsS100B Schizophrenia Psychotic symptoms NIH toolbox cognition battery Cognition
We wish to thank all persons who kindly participated in the study.
Compliance with Ethical Standards
No source of funding was available for this study.
Conflict of Interest
Dr. Jair C. Soares has received grant/research support from BMS, Forest, Merck, Elan, and J&J, support as consultant at Astellas, and support to Speakers Bureau at Pfizer and Abbott. All other authors declare that they have no conflicts of interest.
All procedures were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
- 15.Steiner J, Bielau H, Bernstein H-G, Bogerts B, Wunderlich MT. Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry 2006; 77:1284–1287.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Whitaker-Azmitia PM, Wingate M, Borella A, Gerlai R, Roder J, Azmitia EC. Transgenic mice overexpressing the neurotrophic factor S-100β show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer’s disease and Down’s syndrome. Brain Res 1997; 776:51–60.CrossRefPubMedGoogle Scholar
- 23.Pedersen A, Diedrich M, Kaestner F, Koelkebeck K, Ohrmann P, Ponath G, Kipp F, Abel S, Siegmund A, Suslow T, von Eiff C, Arolt V, Rothermundt M. Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog Neuro-Psychopharmacology Biol Psychiatry 2008; 32:1789–1792.CrossRefGoogle Scholar
- 25.Sheehan D V, Janavs J, Baker R, Harnett-Sheehan K, Knapp E, Sheehan M, Lecrubier Y, Weiller E, Hergueta T, Amorim P, others. MINI-Mini International neuropsychiatric interview-english version 5.0. 0-DSM-IV. J Clin Psychiatry 1998; 59:34–57.Google Scholar
- 28.Zelazo PD, Bauer PJ. National institutes of health toolbox cognition battery (NIH Toolbox CB): Validation for children between 3 and 15 years. Wiley; 2013.Google Scholar
- 30.Morera-Fumero AL, Díaz-Mesa E, Abreu-Gonzalez P, Fernandez-Lopez L, Cejas-Mendez M del R. Day/night changes in serum S100B protein concentrations in acute paranoid schizophrenia. Prog Neuro-Psychopharmacology Biol Psychiatry 2017; 75:207–212.Google Scholar